Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2016-08-11

Last Posted Date: 2016-08-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 63

Registration Number: NCT02864199

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Phase 3

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Biological: Ocrelizumab

First Posted Date: 2016-08-10

Last Posted Date: 2022-01-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 681

Registration Number: NCT02861014

Locations: 🇫🇷
Hôpital Maison Blanche; Service de Neurologie, Reims, France
🇫🇷
Hôpitaux Universitaires de strasbourg - hôpital civil, Strasbourg, France
🇩🇪
Gesundheitszentrum St. Johannes Hospital; Neurolog. Gemeinschaftspraxis Dres. Schmidt, Neudecker etc, Bonn, Germany

and more 160 locations

APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Pegylated interferon (PEG-INF) alfa-2a
Drug: Ribavirin

First Posted Date: 2016-07-29

Last Posted Date: 2017-10-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 385

Registration Number: NCT02850289

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: Emicizumab
Drug: Factor VIII (FVIII)

First Posted Date: 2016-07-28

Last Posted Date: 2022-11-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 152

Registration Number: NCT02847637

Locations: 🇮🇹
AOU Careggi; SOD Malattie Emorragiche, Firenze, Toscana, Italy
🇺🇸
University of Florida, Gainesville, Florida, United States
🇩🇪
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany

and more 36 locations

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Epirubicin

First Posted Date: 2016-07-27

Last Posted Date: 2016-07-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 182

Registration Number: NCT02846428

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Active, not recruiting

Conditions: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

Interventions: Drug: Alectinib
Drug: Crizotinib

First Posted Date: 2016-07-20

Last Posted Date: 2024-09-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 187

Registration Number: NCT02838420

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Guangdong General Hospital, Guangzhou, China
🇨🇳
Shanghai chest hospital, Shanghai, China

and more 18 locations

A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Olesoxime

First Posted Date: 2016-07-18

Last Posted Date: 2016-07-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT02835976

A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Anti-EGFR-Containing Regimen
Drug: Bevacizumab-containing regimen
Drug: Chemotherapy

First Posted Date: 2016-07-13

Last Posted Date: 2018-01-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 4278

Registration Number: NCT02831842

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2

Completed

Conditions: Malignant Melanoma
Chronic Myelogenous Leukemia
Renal Cell Carcinoma

Interventions: Drug: Pegylated Interferon Alfa-2a
Drug: Recombinant Interferon Alfa 2a

First Posted Date: 2016-07-12

Last Posted Date: 2017-01-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT02829775

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Idasanutlin
Drug: Placebo
Drug: [13C]-radiolabeled Idasanutlin
Drug: [14C]-radiolabeled Idasanutlin

First Posted Date: 2016-07-12

Last Posted Date: 2017-12-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT02828930

Locations: 🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy